April 22, 2026 —
Regeneron Pharmaceuticals has secured a landmark U.S. FDA approval for its gene therapy Otarmeni, the first-ever genetic medicine approved to treat an inherited form of hearing loss. The therapy targets ultra-rare mutations in the OTOF gene, a condition affecting roughly 50 newborns annually in the United States, and represents a major milestone for both auditory medicine and the broader gene therapy field.
Otarmeni is built on an Adeno-associated virus (AAV) platform, using an engineered viral vector to deliver a functional copy of the OTOF gene directly into cochlear hair cells. These cells then produce otoferlin, a protein essential for transmitting sound signals from the inner ear to the brain. Unlike traditional treatments such as cochlear implants—which convert sound into electrical signals—this approach addresses the underlying genetic cause, with the potential to restore natural hearing.
The therapy is administered via a one-time infusion into the cochlea under general anesthesia, a procedure similar to cochlear implant surgery. Clinical data from the ongoing CHORD study demonstrated strong efficacy, with approximately 80% of evaluable patients showing improved hearing. Notably, some patients achieved near-normal hearing, and many experienced durable benefits over time. The safety profile was generally manageable, with adverse events including middle ear inflammation, dizziness, and procedural discomfort.
The approval was supported by data published in the New England Journal of Medicine and reflects both clinical and regulatory validation of AAV gene therapy in sensory disorders. While the approval is accelerated and requires further long-term follow-up, it establishes a new benchmark for treating genetic hearing loss.
In a notable move, Regeneron announced it will provide Otarmeni at no cost to patients, although administration-related expenses will still need to be addressed through healthcare providers and payers. Despite forgoing direct revenue, the company received a rare pediatric disease priority review voucher from the FDA—an asset that can be sold for hundreds of millions of dollars or used to accelerate future drug approvals.
Otarmeni originated from Decibel Therapeutics, which Regeneron acquired in 2023, highlighting the strategic importance of hearing loss as a therapeutic area. Beyond this single indication, the approval signals broader potential for AAV-based therapies to address more common forms of hearing impairment and other sensory disorders.
Ultimately, this milestone reinforces a key shift in medicine: from assistive devices to genetic restoration, positioning AAV gene therapy as a transformative modality capable of delivering functional cures.
